Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...

Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focus on low-dose GLP-1 combination therapy, ...

Semaglutide drugs (Ozempic, Wegovy, Rybelsus) top user complaints, mainly for GI symptoms * Tirzepatide (Mounjaro) had fewer ...

Choice of therapy to control high blood sugar may affect survival among older adults with cancer and type 2 diabetes, according to study results.Those who used GLP-1 receptor agonists exhibited ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...